%0 Journal Article
%A Ruiz de Adana, Maria S
%A Alhambra-Exposito, Maria Rosa
%A Muñoz-Garach, Araceli
%A Gonzalez-Molero, Inmaculada
%A Colomo, Natalia
%A Torres-Barea, Isabel
%A Aguilar-Diosdado, Manuel
%A Carral, Florentino
%A Serrano, Manuel
%A Martinez-Brocca, Maria A
%A Duran, Ana
%A Palomares, Rafael
%T Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA1c in Andalusia (Spain): PLATEDIAN Study.
%D 2019
%U http://hdl.handle.net/10668/14823
%X To assess the impact of a telemedicine visit using the platform Diabetic compared with a face-to-face visit on clinical outcomes, patients' health-related quality of life (HRQoL), and physicians' satisfaction in patients with type 1 diabetes. PLATEDIAN (Telemedicine on Metabolic Control in Type 1 Diabetes Mellitus Andalusian Patients) (NCT03332472) was a multicenter, randomized, 6-month follow-up, open-label, parallel-group controlled study performed in patients with type 1 diabetes with suboptimal metabolic control (HbA1c  At month 6, the mean change in HbA1c levels was -0.04 ± 0.5% (-0.5 ± 5.8 mmol/mol) in the CC and 0.01 ± 0.6% (0.1 ± 6.0 mmol/mol) in the IC (P = 0.4941). The number of patients who achieved HbA1c  The use of telemedicine in patients with type 1 diabetes with HbA1cc <8% (<64 mmol/mol) provides similar efficacy and safety outcomes as face-to-face visits.
%K Área de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
%K Blood glucose
%K Diabetes Mellitus, type 1
%K Dose-response relationship, drug
%K Follow-up studies
%K Glycated hemoglobin
%~